Cover Image
市場調查報告書

肺動脈性高血壓 : 開發中產品分析

Pulmonary Arterial Hypertension - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 213126
出版日期 內容資訊 英文 266 Pages
訂單完成後即時交付
價格
Back to Top
肺動脈性高血壓 : 開發中產品分析 Pulmonary Arterial Hypertension - Pipeline Review, H2 2017
出版日期: 2017年09月12日 內容資訊: 英文 266 Pages
簡介

所謂肺動脈性高血壓,是肺動脈(從心臟到肺,輸送帶氧血液的動脈)內部血壓上升這樣的疾病。主要的症狀有胸部疼痛,倦怠感和暈眩,昏厥,腳踝·腿部腫脹(水腫)等。除了家族病史,年齡,肥胖,阻塞型睡眠呼吸中止症(OSA)之外,先天性心臟病,肺病,肝臟病,硬皮症和紅斑性狼瘡等結締組織系統障礙等疾病都是危險因子。主要的治療藥有抗凝結劑和利尿劑、血管擴張藥等。

本報告提供全球各國治療肺動脈高血壓(PAH)所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

肺動脈性高血壓概要

治療藥的開發

  • 肺動脈性高血壓開發中產品:概要
  • 各企業的肺動脈性高血壓治療藥
  • 各大學/研究機關的肺動脈性高血壓治療藥
  • 肺動脈性高血壓治療藥:開發中的產品一覽(各企業)
  • 肺動脈性高血壓治療藥:研究中的產品一覽(各大學/研究機關)

肺動脈性高血壓:治療藥的評估

  • 標的別
  • 各作用機制
  • 各投藥法
  • 各分子類型

肺動脈性高血壓開發治療藥的企業

  • Actelion Ltd
  • Aerogen Ltd.
  • Arena Pharmaceuticals Inc
  • Ascendis Pharma A/S
  • Asklepion Pharmaceuticals LLC
  • AVEO Pharmaceuticals Inc
  • Bial - Portela & Ca SA
  • Biogen Inc.
  • Bristol-Myers Squibb Company
  • Camurus AB
  • Capricor Therapeutics Inc
  • Celsion Corp
  • Celtaxsys Inc
  • Chiesi Farmaceutici SpA
  • 中外製藥
  • Complexa Inc
  • Eli Lilly and Company
  • Galectin Therapeutics Inc
  • GlaxoSmithKline Plc
  • HitGen LTD.
  • Insmed Inc.
  • Insys Therapeutics Inc
  • Johnson & Johnson
  • Liquidia Technologies Inc
  • MannKind Corp
  • Mezzion Pharma Co Ltd
  • 日本化藥
  • 日本新藥
  • 日產化學工業
  • Northern Therapeutics Inc
  • Novartis AG.
  • Peloton Therapeutics Inc
  • PhaseBio Pharmaceuticals Inc
  • Pluristem Therapeutics Inc
  • Polyphor Ltd.
  • Pulmokine Inc
  • Reata Pharmaceuticals Inc
  • Respira Therapeutics Inc
  • Reviva Pharmaceuticals Inc
  • Savara Inc.
  • Serodus ASA
  • Silence Therapeutics Plc
  • SteadyMed Therapeutics Inc
  • Suda Ltd.
  • 武田藥品工業
  • Toray Industries
  • United Therapeutics Corp
  • Vicore Pharma AB
  • Vivus Inc

藥物簡介

肺動脈性高血壓治療藥:開發暫停的產品

肺動脈性高血壓治療藥:開發中止的產品

肺動脈性高血壓相關產品的開發里程碑

  • 值得注意的最新趨勢·新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9678IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pulmonary Arterial Hypertension - Pipeline Review, H2 2017, provides an overview of the Pulmonary Arterial Hypertension (Cardiovascular) pipeline landscape.

Pulmonary arterial hypertension (PAH) is a type of high blood pressure that occurs in the right side of the heart and in the arteries that supply blood to the lungs. Symptoms include chest pain, fatigue, passing out suddenly, and swelling of the legs (edema). Risk factors include family history, age, obesity, obstructive sleep apnea and other diseases, including congenital heart disease, lung disease, liver disease and connective tissue disorders like scleroderma and lupus. Treatment includes sildenafil, prostanoids and calcium channel blockers.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Pulmonary Arterial Hypertension - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Pulmonary Arterial Hypertension (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pulmonary Arterial Hypertension (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Pulmonary Arterial Hypertension and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 6, 9, 20, 39, 3 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 2 molecules, respectively.

Pulmonary Arterial Hypertension (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Pulmonary Arterial Hypertension (Cardiovascular).
  • The pipeline guide reviews pipeline therapeutics for Pulmonary Arterial Hypertension (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Pulmonary Arterial Hypertension (Cardiovascular) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Pulmonary Arterial Hypertension (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Pulmonary Arterial Hypertension (Cardiovascular)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Pulmonary Arterial Hypertension (Cardiovascular).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Pulmonary Arterial Hypertension (Cardiovascular) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Pulmonary Arterial Hypertension - Overview
  • Pulmonary Arterial Hypertension - Therapeutics Development
  • Pulmonary Arterial Hypertension - Therapeutics Assessment
  • Pulmonary Arterial Hypertension - Companies Involved in Therapeutics Development
  • Pulmonary Arterial Hypertension - Drug Profiles
  • Pulmonary Arterial Hypertension - Dormant Projects
  • Pulmonary Arterial Hypertension - Discontinued Products
  • Pulmonary Arterial Hypertension - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Pulmonary Arterial Hypertension, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..2), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..3), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..4), H2 2017
  • Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017
  • Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Pulmonary Arterial Hypertension - Pipeline by Actelion Ltd, H2 2017
  • Pulmonary Arterial Hypertension - Pipeline by Aerogen Ltd, H2 2017
  • Pulmonary Arterial Hypertension - Pipeline by Arena Pharmaceuticals Inc, H2 2017
  • Pulmonary Arterial Hypertension - Pipeline by Ascendis Pharma A/S, H2 2017
  • Pulmonary Arterial Hypertension - Pipeline by Asklepion Pharmaceuticals LLC, H2 2017
  • Pulmonary Arterial Hypertension - Pipeline by AVEO Pharmaceuticals Inc, H2 2017
  • Pulmonary Arterial Hypertension - Pipeline by Bial - Portela & Ca SA, H2 2017
  • Pulmonary Arterial Hypertension - Pipeline by Biogen Inc, H2 2017
  • Pulmonary Arterial Hypertension - Pipeline by Bristol-Myers Squibb Company, H2 2017
  • Pulmonary Arterial Hypertension - Pipeline by Camurus AB, H2 2017
  • Pulmonary Arterial Hypertension - Pipeline by Capricor Therapeutics Inc, H2 2017
  • Pulmonary Arterial Hypertension - Pipeline by Celsion Corp, H2 2017
  • Pulmonary Arterial Hypertension - Pipeline by Celtaxsys Inc, H2 2017
  • Pulmonary Arterial Hypertension - Pipeline by Chiesi Farmaceutici SpA, H2 2017
  • Pulmonary Arterial Hypertension - Pipeline by Chugai Pharmaceutical Co Ltd, H2 2017
  • Pulmonary Arterial Hypertension - Pipeline by Complexa Inc, H2 2017
  • Pulmonary Arterial Hypertension - Pipeline by Eli Lilly and Company, H2 2017
  • Pulmonary Arterial Hypertension - Pipeline by Galectin Therapeutics Inc, H2 2017
  • Pulmonary Arterial Hypertension - Pipeline by GlaxoSmithKline Plc, H2 2017
  • Pulmonary Arterial Hypertension - Pipeline by HitGen LTD, H2 2017
  • Pulmonary Arterial Hypertension - Pipeline by Insmed Inc, H2 2017
  • Pulmonary Arterial Hypertension - Pipeline by Insys Therapeutics Inc, H2 2017
  • Pulmonary Arterial Hypertension - Pipeline by Johnson & Johnson, H2 2017
  • Pulmonary Arterial Hypertension - Pipeline by Liquidia Technologies Inc, H2 2017
  • Pulmonary Arterial Hypertension - Pipeline by MannKind Corp, H2 2017
  • Pulmonary Arterial Hypertension - Pipeline by Mezzion Pharma Co Ltd, H2 2017
  • Pulmonary Arterial Hypertension - Pipeline by Nippon Kayaku Co Ltd, H2 2017
  • Pulmonary Arterial Hypertension - Pipeline by Nippon Shinyaku Co Ltd, H2 2017
  • Pulmonary Arterial Hypertension - Pipeline by Nissan Chemical Industries Ltd, H2 2017
  • Pulmonary Arterial Hypertension - Pipeline by Northern Therapeutics Inc, H2 2017
  • Pulmonary Arterial Hypertension - Pipeline by Novartis AG, H2 2017
  • Pulmonary Arterial Hypertension - Pipeline by Peloton Therapeutics Inc, H2 2017
  • Pulmonary Arterial Hypertension - Pipeline by PhaseBio Pharmaceuticals Inc, H2 2017
  • Pulmonary Arterial Hypertension - Pipeline by Pluristem Therapeutics Inc, H2 2017
  • Pulmonary Arterial Hypertension - Pipeline by Polyphor Ltd, H2 2017
  • Pulmonary Arterial Hypertension - Pipeline by Pulmokine Inc, H2 2017
  • Pulmonary Arterial Hypertension - Pipeline by Reata Pharmaceuticals Inc, H2 2017
  • Pulmonary Arterial Hypertension - Pipeline by Respira Therapeutics Inc, H2 2017
  • Pulmonary Arterial Hypertension - Pipeline by Reviva Pharmaceuticals Inc, H2 2017
  • Pulmonary Arterial Hypertension - Pipeline by Savara Inc, H2 2017
  • Pulmonary Arterial Hypertension - Pipeline by Serodus ASA, H2 2017
  • Pulmonary Arterial Hypertension - Pipeline by Silence Therapeutics Plc, H2 2017
  • Pulmonary Arterial Hypertension - Pipeline by SteadyMed Therapeutics Inc, H2 2017
  • Pulmonary Arterial Hypertension - Pipeline by Suda Ltd, H2 2017
  • Pulmonary Arterial Hypertension - Pipeline by Takeda Pharmaceutical Company Ltd, H2 2017
  • Pulmonary Arterial Hypertension - Pipeline by Toray Industries Inc, H2 2017
  • Pulmonary Arterial Hypertension - Pipeline by United Therapeutics Corp, H2 2017
  • Pulmonary Arterial Hypertension - Pipeline by Vicore Pharma AB, H2 2017
  • Pulmonary Arterial Hypertension - Pipeline by Vivus Inc, H2 2017
  • Pulmonary Arterial Hypertension - Dormant Projects, H2 2017
  • Pulmonary Arterial Hypertension - Dormant Projects, H2 2017 (Contd..1), H2 2017
  • Pulmonary Arterial Hypertension - Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development for Pulmonary Arterial Hypertension, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Top 10 Targets, H2 2017
  • Number of Products by Stage and Top 10 Targets, H2 2017
  • Number of Products by Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Top 10 Molecule Types, H2 2017
  • Number of Products by Stage and Top 10 Molecule Types, H2 2017
Back to Top